Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 8/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999804 | 0.94 | HTR2A (0.39) | HTR2ASLC6A4KCNH2LGALS8LGALS3 | |
| SCHEMBL6000354 | 0.83 | SOS1 (0.45) | HTR2ASLC6A4KCNH2LGALS8LGALS3 | |
| SCHEMBL6000347 | 0.82 | SLC6A4 (0.51) | HTR2ASLC6A4KCNH2LGALS8LGALS3 | |
| SCHEMBL5999808 | 0.77 | SOS1 (0.46) | HTR2ASLC6A4KCNH2SOS1 | |
| SCHEMBL5999798 | 0.76 | SLC6A4 (0.52) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL5999503 | 0.74 | KCNH2 (0.34) | HTR2ASLC6A4KCNH2KAT6ACHRM2 | |
| SCHEMBL6000267 | 0.69 | FFAR1 (0.38) | HTR2ASLC6A4KCNH2 | |
| Formic Acid SCHEMBL5999505 | 0.67 | CHRM2 (0.36) | HTR2ASLC6A4KCNH2SOS1CHRM2 | |
| Formic Acid SCHEMBL5999499 | 0.65 | SLC6A4 (0.45) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL6000410 | 0.63 | HTR2A (0.39) | HTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | HTR2A 7/4885SLC6A4 150/4885KCNH2 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.